Discovery of direct inhibitor of KRAS oncogenic protein by natural products: a combination of pharmacophore search, molecular docking, and molecular dynamic studies
Background and purpose: Aberrant signaling by oncogenic RAS proteins occurs in almost all human tumors. One of the promising strategies to overcome such cancers is the inhibition of KRAS protein, a subtype of RAS family involved in cell growth, differentiation, and apoptosis, through preventing its...
Main Authors: | Samaneh Hashemi, Amirhossein Sharifi, Sara Zareei, Ghazale Mohamedi, Mahmood Biglar, Massoud Amanlou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Research in Pharmaceutical Sciences |
Subjects: | |
Online Access: | http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2020;volume=15;issue=3;spage=226;epage=240;aulast=Hashemi |
Similar Items
-
In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
by: Yinglan Pu, et al.
Published: (2017-06-01) -
Differential Effector Engagement by Oncogenic KRAS
by: Tina L. Yuan, et al.
Published: (2018-02-01) -
Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson–Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis
by: Mubarak A. Alamri, et al.
Published: (2023-06-01) -
Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
by: Liu X, et al.
Published: (2019-08-01) -
Oncogenic KRAS: Signaling and Drug Resistance
by: Hyeon Jin Kim, et al.
Published: (2021-11-01)